Last reviewed · How we verify
BK-C-0701 320mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BK-C-0701 320mg (BK-C-0701 320mg) — Bukwang Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BK-C-0701 320mg TARGET | BK-C-0701 320mg | Bukwang Pharmaceutical | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BK-C-0701 320mg CI watch — RSS
- BK-C-0701 320mg CI watch — Atom
- BK-C-0701 320mg CI watch — JSON
- BK-C-0701 320mg alone — RSS
Cite this brief
Drug Landscape (2026). BK-C-0701 320mg — Competitive Intelligence Brief. https://druglandscape.com/ci/bk-c-0701-320mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab